Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-α) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-α therapy for chronic myelogenous leukemia. In this case, IFN-α seems to be the only etiological agent.

Keywords:
Chronic myelogenous leukemia, Immunologic effects, Interferon alpha, Thrombotic thrombocytopenic purpura
1.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820–825.
2.
Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906–916.
3.
Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991;114:532–538.
4.
Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J, for the French Chronic Myeloid Leukemia Study Group: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223–229.
5.
Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomized, multicentre trial of interferon-α n1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995;345:1392–1397.
6.
Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986;4:234–243.
7.
Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clarck JW: Exacerbation of symptoms of autoimmune disease in patients receiving α-interferon therapy. Cancer 1990;65:2237–2242.
8.
Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome. Am J Hematol 1994;46:152–153.
9.
Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, Attal M, Laurent G, Pris J: Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994;47:254–255.
10.
Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM: Thrombotic microangiopathy (TM) associated with interferon therapy in chronic myelogenous leukemia (CML): Coincidence or a true side effect? (abstract). Blood 1998;92(suppl 1):4064.
11.
Rachmani R, Avigdor A, Youkla M, Raanani P, Zilber M, Ravid M, Ben-Bassat I: Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-α. Acta Haematol 1998;100:204–206.
12.
Teichmann J, Siebber G, Ludwig W, Ruehl H: Immunosuppressive effects of recombinant IFN-α during long-term treatment of cancer patients. Cancer 1989;63:1990–1993.
13.
Carlson K, Smedmyr B, Hagberg H, Öberg G, Simonsson B: Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-c, cyclophosphamide) versus TBI and autologous BMT for malignant lymphomas. Bone Marrow Transplant 1993;11:205–208.
14.
Shammas F, Meyer P, Heikkila R, Apeland T, Goransson L, Berland J, Kjellevold K: Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Acta Haematol 1997;97:184–186.
15.
Nield GH: Hemolytic-uremic syndrome in practice. Lancet 1994;143:398–401.
16.
Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer L, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578–1584.
© 2000 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.